Impulsonics, a medical device startup developing advanced acoustic wave-based cell technology, has secured £450,000 ( approximately $573,338) in early-stage funding, the University of Bristol announced on May 2, 2024. The funding will help simplify the work of cell researchers with its contactless cell-moving technology.
According to the press release, SFC Capital led the startup’s funding round, which also received investments from British Business Investments, the University of Bristol, and angel investors.
The recently raised capital will help Impulsonic accelerate the development and testing of the biotech platform, advancing the company’s mission of turning unique scientific innovations into scalable approaches for use in research and healthcare.
Founded by Dr Luke Cox, Dr James Armstrong, Dr Amanda Franklin, Professors Bruce Drinkwater and Anthony Croxford as a spin-out from Bristol University’s Ultrasonics & NDT Group, the Impulsonics team is using acoustic manipulation to develop a biotech platform that can help automate some research processes for cell scientists, saving time and cost.
The startup’s innovative technology will help transform lab-scale cell culture techniques into a reliable industrial process critical for drug discovery and healthcare applications, automating the traditionally manual and time-consuming processes.
This is particularly important in the 21st century due to the rise of AI drug discovery demanding enormous volumes of high-quality data, far beyond what the traditional processes can yield.
